Entero Healthcare Solutions Ltd (ENTERO) — shareholding pattern, promoter holding, financials and share price
About Entero Healthcare Solutions Ltd (ENTERO)
Entero Healthcare Solutions Ltd operates in the Pharmacy Retail industry, within the Consumer Services sector. It trades on the NSE as ENTERO and on the BSE under scrip code 544122. Its ISIN is INE010601016.
Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services [1]
Entero Healthcare Solutions Limited is an integrated, technology-enabled healthcare products distributor operating a pan‑India supply chain that distributes pharmaceuticals, medical devices, surgical consumables, OTC and nutraceuticals to retail pharmacies and hospitals, backed by a network of warehouses, proprietary platforms and an acquisitive growth strategy.
The company reported strong Q3FY26 performance: consolidated revenue of Rs.1,706.5 crore (+25.6% YoY), gross margin improvement to 10.1%, EBITDA of Rs.67.8 crore (+35.5% YoY) and positive operating cash flow of Rs.49 crore driven by improved NWC and margin expansion initiatives.
Listed peers in Pharmacy Retail: Arvind Fashions Ltd, V-Mart Retail Ltd, Electronics Mart India Ltd, RattanIndia Enterprises Ltd, Just Dial Ltd, Shoppers Stop Ltd.
Valuation & Returns
10 Jul 2026At ₹1,205 a share on 10 Jul 2026, Entero Healthcare Solutions Ltd (ENTERO) was valued at a price-to-earnings ratio of 35.96x against an industry P/E of 78.58x and a price-to-book of 3.04x on a book value of ₹396.15 per share as of Mar 2025. Solomo computes return on equity of 8.46% and return on capital employed of 11.08% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 35.96x
- Industry P/E
- 78.58x
- P/B
- 3.04x
- EPS (TTM)
- ₹33.51
- Book value / share
- ₹396.15
- ROE
- 8.46%
- ROCE
- 11.08%
- ROA
- 5.4%
- Debt / equity
- 0.22x
- Dividend yield
- 0%
- EBITDA margin
- 4.2%
- 52-week range
- ₹944 – ₹1,390
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Entero Healthcare Solutions Ltd (ENTERO) reported revenue of ₹6,591 crore, net profit of ₹146 crore and earnings per share of ₹26.44. That compares with revenue of ₹5,096 crore and net profit of ₹107 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,910 crore and net profit ₹45 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2,522 | 3,300 | 3,922 | 5,096 | 6,591 |
| Net profit (₹ cr) | -29 | -11 | 40 | 107 | 146 |
| EPS (₹) | -77.71 | -28.12 | 8.99 | 21.79 | 26.44 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 48.81% | 43.85% | 29.92% |
| Profit growth | - | - | 169.92% |
| Stock price CAGR | - | - | 1% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.4% of Entero Healthcare Solutions Ltd (ENTERO) (down 0.02 pp QoQ), foreign institutional investors (FII) hold 4.37% and domestic institutional investors (DII) hold 15.48%. Market capitalisation was ₹5,245 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2024.
Largest disclosed public shareholders in Jun 2026: SURBHI SINGH(PRASID UNO FAMILY TRUST) 10.45%, Invesco India Aggressive Hybrid Fund 4.31%, Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund 2.16%, Bank Of India Flexi Cap Fund 2.12%, Cif Iii Scheme I 1.95%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.4% | - | 4.37% | 15.48% | 47.6% |
| Mar 2026 | 52.42% | - | 4.03% | 16.62% | 47.58% |
| Dec 2025 | 52.42% | - | 5.14% | 16.42% | 47.58% |
| Sep 2025 | 52.42% | - | 14.67% | 9.65% | 47.58% |
| Jun 2025 | 52.42% | - | 17.2% | 10.18% | 47.58% |
| Mar 2025 | 52.42% | - | 19.92% | 9.64% | 47.58% |
| Dec 2024 | 52.44% | - | 22.21% | 8.77% | 47.56% |
| Sep 2024 | 52.44% | - | 23.82% | 7.73% | 47.56% |